Prognostic impact of early-versus-late ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: results from the calm study by the cmwp of the ebmt
Auteur(s) :
Garderet, Laurent [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université [SU]
Centre de Recherche Saint-Antoine [CRSA]
Sbianchi, Giulia [Auteur]
Iacobelli, Simona [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Byrne, J. L. [Auteur]
Remenyi, Peter [Auteur]
Apperley, Jane F. [Auteur]
Touzeau, Cyrille [Auteur]
Centre Hospitalier Universitaire de Nantes [CHU Nantes]
Isaksson, Cecilia [Auteur]
Browne, Paul [Auteur]
Mayer, Jiri [Auteur]
Lenhoff, Stig [Auteur]
Gonzalez Muniz, Soledad [Auteur]
Parody Porras, Rocio [Auteur]
Basak, Grzegorz W. [Auteur]
Poire, Xavier [Auteur]
Trneny, Marek [Auteur]
Nagler, Arnon [Auteur]
Michieli, Mariagrazia [Auteur]
Tanase, Alina [Auteur]
Koster, Linda [Auteur]
Hayden, Patrick J. [Auteur]
Beksac, Meral [Auteur]
Schonland, Stefan O. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
CHU Pitié-Salpêtrière [AP-HP]
Sorbonne Université [SU]
Centre de Recherche Saint-Antoine [CRSA]
Sbianchi, Giulia [Auteur]
Iacobelli, Simona [Auteur]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Byrne, J. L. [Auteur]
Remenyi, Peter [Auteur]
Apperley, Jane F. [Auteur]
Touzeau, Cyrille [Auteur]
Centre Hospitalier Universitaire de Nantes [CHU Nantes]
Isaksson, Cecilia [Auteur]
Browne, Paul [Auteur]
Mayer, Jiri [Auteur]
Lenhoff, Stig [Auteur]
Gonzalez Muniz, Soledad [Auteur]
Parody Porras, Rocio [Auteur]
Basak, Grzegorz W. [Auteur]
Poire, Xavier [Auteur]
Trneny, Marek [Auteur]
Nagler, Arnon [Auteur]
Michieli, Mariagrazia [Auteur]
Tanase, Alina [Auteur]
Koster, Linda [Auteur]
Hayden, Patrick J. [Auteur]
Beksac, Meral [Auteur]
Schonland, Stefan O. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Titre de la revue :
European Journal of Haematology
Nom court de la revue :
Eur J Haematol
Date de publication :
2021-02-12
ISSN :
1600-0609
Mot(s)-clé(s) :
multiple myeloma
autologous transplantation
induction regimen
kinetics of response
autologous transplantation
induction regimen
kinetics of response
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: In autologous stem cell transplant (ASCT)-eligible myeloma patients, prolonged induction does not necessarily improve the depth of response.
METHODS: We analyzed 1222 ASCT patients who were classified based ...
Lire la suite >BACKGROUND: In autologous stem cell transplant (ASCT)-eligible myeloma patients, prolonged induction does not necessarily improve the depth of response. METHODS: We analyzed 1222 ASCT patients who were classified based on (a) the interval between induction and stem cell collection, (b) the type of induction regimen: BID (Bortezomib, IMiDs, and Dexamethasone), Bortezomib-based, or CTD (Cyclophosphamide, Thalidomide, and Dexamethasone), and (c) the time to best response (Early ie, best response within 4 or 5 months, depending on the regimen vs Late; Good ie, VGPR or better vs Poor). RESULTS: The length of induction treatment required to achieve a Good response did not affect PFS (P = .65) or OS (P = .61) post-ASCT. The three types of regimen resulted in similar outcomes: median PFS 31, 27.7 and 30.8 months (P = .31), and median OS 81.7, 92.7, and 77.4 months, respectively (P = .83). On multivariate analysis, neither the type nor the duration of the induction regimen affected OS and PFS, except for Early Good Responders who had a better PFS compared to Early Poor Responders (HR = 1.21, P-value = .02). However, achieving a Good response at induction was associated with a better response (≥VGPR) post-transplant. CONCLUSIONS: The kinetics of response did not affect outcomes.Lire moins >
Lire la suite >BACKGROUND: In autologous stem cell transplant (ASCT)-eligible myeloma patients, prolonged induction does not necessarily improve the depth of response. METHODS: We analyzed 1222 ASCT patients who were classified based on (a) the interval between induction and stem cell collection, (b) the type of induction regimen: BID (Bortezomib, IMiDs, and Dexamethasone), Bortezomib-based, or CTD (Cyclophosphamide, Thalidomide, and Dexamethasone), and (c) the time to best response (Early ie, best response within 4 or 5 months, depending on the regimen vs Late; Good ie, VGPR or better vs Poor). RESULTS: The length of induction treatment required to achieve a Good response did not affect PFS (P = .65) or OS (P = .61) post-ASCT. The three types of regimen resulted in similar outcomes: median PFS 31, 27.7 and 30.8 months (P = .31), and median OS 81.7, 92.7, and 77.4 months, respectively (P = .83). On multivariate analysis, neither the type nor the duration of the induction regimen affected OS and PFS, except for Early Good Responders who had a better PFS compared to Early Poor Responders (HR = 1.21, P-value = .02). However, achieving a Good response at induction was associated with a better response (≥VGPR) post-transplant. CONCLUSIONS: The kinetics of response did not affect outcomes.Lire moins >
Langue :
Anglais
Comité de lecture :
Oui
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Date de dépôt :
2021-07-06T12:49:57Z
2024-03-04T15:47:43Z
2024-03-04T15:47:43Z